# Viracor-IBT Laboratories Acquires Assets of Cylex

PR Newswire

LEE'S SUMMIT, Mo., Feb. 5, 2013 /PRNewswire/ -- Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex™, Inc., a global life sciences company focused on the development, manufacturing and commercialization of *in vitro* diagnostic products intended to illuminate immunity in the area of transplant medicine. This includes the acquisition of Cylex's core product, ImmuKnow®, a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in populations undergoing immunosuppressive therapy for organ transplant. The transaction is expected to close February 8, 2013.

ImmuKnow®, when used as part of a global immune status monitoring strategy, can help clinicians optimize immunosuppression in organ transplant recipients for kidney, liver, lung and heart transplants.

"As a leader in molecular and immunodiagnostics, Viracor-IBT has been proud to offer the ImmuKnow assay to its clients for nearly a decade to assist clinicians in making critical decisions for patients undergoing transplants through the use of specialized diagnostics and the accelerated delivery of information. We're confident this acquisition will result in continued benefits to the industry, our clients and to the patients we serve. Throughout the transition, Viracor-IBT is committed to ensuring continued access to ImmuKnow through the current avenues of kit purchases and laboratory testing," said Thomas W. Burnell , PhD, President and CEO of Viracor-IBT Laboratories.

**Source URL (retrieved on *03/27/2015 - 4:33am*):**
http://www.mdtmag.com/news/2013/02/viracor-ibt-laboratories-acquires-assets-cylex